ArticleApplied and environmental microbiology2012
Lactobacillus reuteri protects epidermal keratinocytes from Staphylococcus aureus-induced cell death by competitive exclusion.
Article in Applied and environmental microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Use of probiotics to correct dysbiosis of normal microbiota following disease or disruptive events: a systematic review.BMJ open · 2014Pooled it
- The probiotic Lactiplantibacillus plantarum ATCC10241 inhibits wound-associated pathogens through the secretion of organic acids.Scientific reports · 2026Article
- The Role of ProbioticsInternational journal of molecular sciences · 2026Review
- Topical Probiotics as a Novel Approach in the Treatment of Chronic Dermatoses Associated with Skin Dysbiosis: A Narrative Review.International journal of molecular sciences · 2025Review
- A computational framework for inferring species dynamics and interactions with applications in microbiota ecology.NPJ systems biology and applications · 2025Article
- Ligilactobacillus salivarius Lac45 inhibits MRSA and suppresses inflammation in human keratinocyte.Archives of dermatological research · 2025Article
- Leveraging Microorganisms to Combat Skin Cancer.Microorganisms · 2025Review
- Lactobacillus lysates protect oral epithelial cells from pathogen-associated damage, increase secretion of pro-inflammatory cytokines and enhance barrier integrity.Scientific reports · 2025Article
- Navigating a challenging path: precision disease treatment with tailored oral nano-armor-probiotics.Journal of nanobiotechnology · 2025Review
- Modulations of the skin microbiome in skin disorders: A narrative review from a wound care perspective.International wound journal · 2024Review
- Postbiotic lactobacilli induce cutaneous antimicrobial response and restore the barrier to inhibit the intracellular invasion of Staphylococcus aureus in vitro and ex vivo.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2024Article
- Carbon source competition within the wound microenvironment can significantly influence infection progression.NPJ biofilms and microbiomes · 2024Article
- A survey of multiple candidate probiotic bacteria reveals specificity in the ability to modify the effects of key wound pathogens.Microbiology spectrum · 2024Article
- Looking for the Ideal Probiotic Healing Regime.Nutrients · 2023Review
- Using theMicrobiology (Reading, England) · 2023Article
- The role of potential probiotic strainsFrontiers in microbiology · 2023Review
- Healing wounds, defeating biofilms:Frontiers in microbiology · 2023Article
- The Antimicrobial Effect of Various Single-Strain and Multi-Strain Probiotics, Dietary Supplements or Other Beneficial Microbes against Common Clinical Wound Pathogens.Microorganisms · 2022Article
- Article
- Development and metabolic profiling of a postbiotic complex exhibiting antibacterial activity against skin microorganisms and anti-inflammatory effect on human keratinocytes.Food science and biotechnology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Recent studies have suggested that the topical application of probiotic bacteria can improve skin health or combat disease. We have utilized a primary human keratinocyte culture model to investigate whether probiotic bacteria can inhibit Staphylococcus aureus infection. Evaluation of the candidate probiotics Lactobacillus reuteri ATCC 55730, Lactobacillus rhamnosus AC413, and Lactobacillus salivarius UCC118 demonstrated that both L. reuteri and L. rhamnosus, but not L. salivarius, reduced S. aureus-induced keratinocyte cell death in both undifferentiated and differentiated keratinocytes. Keratinocyte survival was significantly higher if the probiotic was applied prior to (P < 0.01) or simultaneously with (P < 0.01) infection with S. aureus but not when added after infection had commenced (P > 0.05). The protective effect of L. reuteri was not dependent on the elaboration of inhibitory substances such as lactic acid. L. reuteri inhibited adherence of S. aureus to keratinocytes by competitive exclusion (P = 0.026). L. salivarius UCC118, however, did not inhibit S. aureus from adhering to keratinocytes (P > 0.05) and did not protect keratinocyte viability. S. aureus utilizes the α5β1 integrin to adhere to keratinocytes, and blocking of this integrin resulted in a protective effect similar to that observed with probiotics (P = 0.03). This suggests that the protective mechanism for L. reuteri-mediated protection of keratinocytes was by competitive exclusion of the pathogen from its binding sites on the cells. Our results suggest that use of a topical probiotic prophylactically could inhibit the colonization of skin by S. aureus and thus aid in the prevention of infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.